Anika Therapeutics Stock
Anika Therapeutics Stock
Anika Therapeutics dominated the market today, gaining €1.40 (10.530%).
Currently there is a rather positive sentiment for Anika Therapeutics with 5 Buy predictions and 0 Sell predictions.
However, we have a potential of -4.76% for Anika Therapeutics as the target price of 14 € is below the current price of 14.7 €.
For the coming years our community has positive and negative things to say abot the Anika Therapeutics stock. Criterium "Brand" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Anika Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Anika Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Anika Therapeutics | 10.530% | 19.512% | 16.667% | 104.167% | 83.750% | -32.569% | -57.018% |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
Comments
Anika Therapeutics (ANIK) had its "buy" rating reaffirmed by B. Riley Financial, Inc..
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (ANIK) had its price target raised by Barrington Research from $16.00 to $17.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (NASDAQ:ANIK) had its price target raised by analysts at Barrington Research from $15.00 to $16.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
News
Anika Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Anika Therapeutics Inc.? Here are five stocks we like better.
- Second-quarter performance strengthened: Revenue rose 16% year over year to $32.6 million, while gross
